NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H1 2018
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H1 2018
SUMMARY
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Oncology, Respiratory, Gastrointestinal, Immunology, Toxicology and Undisclosed which include indications Idiopathic Pulmonary Fibrosis, Acute Ischemic Stroke, Atherosclerosis, Chlorine Poisoning, Diabetic Complications, Diabetic Nephropathy, Ischemia Reperfusion Injury, Liver Fibrosis, Lung Cancer, Mustard Gas (Sulfur Mustard) Poisoning, Nerve Gas Poisoning, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Prostate Cancer, Pulmonary Radiation Toxicity, Systemic Sclerosis (Scleroderma), Type 2 Diabetes and Unspecified.
The latest report NADPH Oxidase 4 - Pipeline Review, H1 2018, outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Oncology, Respiratory, Gastrointestinal, Immunology, Toxicology and Undisclosed which include indications Idiopathic Pulmonary Fibrosis, Acute Ischemic Stroke, Atherosclerosis, Chlorine Poisoning, Diabetic Complications, Diabetic Nephropathy, Ischemia Reperfusion Injury, Liver Fibrosis, Lung Cancer, Mustard Gas (Sulfur Mustard) Poisoning, Nerve Gas Poisoning, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Prostate Cancer, Pulmonary Radiation Toxicity, Systemic Sclerosis (Scleroderma), Type 2 Diabetes and Unspecified.
The latest report NADPH Oxidase 4 - Pipeline Review, H1 2018, outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
- The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects
- The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals Inc
GenKyoTex SA
Glucox Biotech AB
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles
AEOL-10150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit NOX4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Type-2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Discontinued Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2017: Genkyotex Provides Business Update For Q3 2017
Sep 20, 2017: Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy after Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
Aug 03, 2017: Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts
Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Jun 08, 2017: Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients with Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
Mar 23, 2017: Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification
Feb 22, 2017: Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
Feb 17, 2017: Aeolus Announces First Quarter 2017 Financial Results
Sep 19, 2016: Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"
Sep 06, 2016: Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure against Sulfur Mustard Gas
May 23, 2016: Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Feb 22, 2016: Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016
Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis
Nov 04, 2015: Aeolus Announces Formation of Pulmonary Fibrosis Clinical Advisory Board
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals Inc
GenKyoTex SA
Glucox Biotech AB
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles
AEOL-10150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit NOX4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Type-2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Discontinued Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2017: Genkyotex Provides Business Update For Q3 2017
Sep 20, 2017: Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy after Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
Aug 03, 2017: Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts
Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Jun 08, 2017: Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients with Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
Mar 23, 2017: Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification
Feb 22, 2017: Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
Feb 17, 2017: Aeolus Announces First Quarter 2017 Financial Results
Sep 19, 2016: Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"
Sep 06, 2016: Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure against Sulfur Mustard Gas
May 23, 2016: Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Feb 22, 2016: Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016
Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis
Nov 04, 2015: Aeolus Announces Formation of Pulmonary Fibrosis Clinical Advisory Board
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
Pipeline by GenKyoTex SA, H1 2018
Pipeline by Glucox Biotech AB, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
Pipeline by GenKyoTex SA, H1 2018
Pipeline by Glucox Biotech AB, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aeolus Pharmaceuticals Inc
GenKyoTex SA
Glucox Biotech AB
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aeolus Pharmaceuticals Inc
GenKyoTex SA
Glucox Biotech AB
